Acta Endoscopica

, Volume 42, Issue 1, pp 36–38 | Cite as

Œsophage de Barrett : surveillance ou traitement au stade non dysplasique ou en dysplasie de bas grade

Commentaire D’Article / Article Comment
  • 47 Downloads

Barrett’s oesophagus: monitoring or treatment of non-dysplastic or low-grade dysplasia

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Wani S, Falk G, Hall M, Gaddam S, Wang A, Gupta N, et al. Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011;9:220–227.PubMedCrossRefGoogle Scholar
  2. 2.
    Wani S, Falk GW, Post J, Yerian L, Hall M, Wang A, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology 2011;141:1179–1186.PubMedCrossRefGoogle Scholar
  3. 3.
    Sharma P, Falk GW, Falk GW, P Weston AP, P, P Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 2006;4:566–572.PubMedCrossRefGoogle Scholar
  4. 4.
    de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. R isk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut 2010;59:1030–1036.PubMedCrossRefGoogle Scholar
  5. 5.
    Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011;103:1049–1057.PubMedCrossRefGoogle Scholar
  6. 6.
    Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:235–244.PubMedCrossRefGoogle Scholar
  7. 7.
    Wani S, Puli SR, Shaheen NJ, Westhoff B, Slehria S, Bansal A, et al. Esophageal adenocarcinoma in Barrett’s esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol 2009;104:502–513.PubMedCrossRefGoogle Scholar
  8. 8.
    Srivastava A, Hornick JL, Li X, Blount PL, Sanchez CA, Cowan DS, et al. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett’s esophagus. Am J Gastroenterol 2007;102:483–493.PubMedCrossRefGoogle Scholar
  9. 9.
    Dar MS, Goldblum JR, Rice TW, Falk GW. Can extent of high W, Falk GW. Can extent of high W grade dysplasia in Barrett’s oesophagus predict the presence of adenocarcinoma at oesophagectomy Gut 2003;52:486–489PubMedCrossRefGoogle Scholar
  10. 10.
    Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, et al. Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630–1639.PubMedCrossRefGoogle Scholar
  11. 11.
    Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009:28; 360:2277–2288.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France 2011

Authors and Affiliations

  1. 1.Unité d’endoscopie digestive et bronchiquecentre hospitalier de CannesCannesFrance

Personalised recommendations